Jul 28, 2026 8:05am EDT Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
Jun 16, 2026 4:01pm EDT Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
May 21, 2026 5:17pm EDT Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
May 14, 2026 8:05am EDT Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026 7:00am EDT Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
Apr 28, 2026 8:05am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
